Log In
Print this Print this

lenzilumab (KB003)

  Manage Alerts
Collapse Summary General Information
Company KaloBios Pharmaceuticals Inc.
DescriptionChimeric mAb against GM-CSF developed using Humaneered technology
Molecular Target Granulocyte macrophage colony-stimulating factor (GM-CSF) receptor (CSF2RA) (GMR) (CD116)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationChronic myelogenous leukemia (CML)
Indication DetailsTreat chronic myelomonocytic leukemia (CMML) in patients who have received prior therapy
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today